\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div> <\/p>\n<\/div><\/section> <\/p>\n The funds will be used to complete IND-enabling work and to initiate the clinical development of Kupando\u2019s lead candidate KUP101 in a solid tumour indication. KUP101 is the only TLR 4\/7 agonist in development, and consists of two small molecules, a TLR 4 agonist and a TLR 7 agonist, co-encapsulated in a liposomal formulation. The compounds induce a broad immune response, which will facilitate their development as an anti-tumour agent, as a stand-alone product, in combination with other anti-tumour modalities, or a prophylactic vaccine for infectious diseases. The induction of cross-reactive anti-bodies and a broad cellular response are promising features for a broad portfolio of indications, in particular where different strains and antigens play a role, like influenza, HPV and others. A high target specificity in the absence of relevant off-targets are indicators for a promising safety profile.<\/p>\n The investment was led by Remiges Ventures and co-led by LifeCare Partners with an additional investment by Brandenburg Kapital, High-Tech Gr\u00fcnderfonds, Ventura Biomed Investors and undisclosed family offices.<\/p>\n Kazuhiko Nonomura, PhD Principal at Remiges Ventures, the lead investor said: \u201cWe are impressed by the tremendous progress made by Kupando since its inception. Kupando is a real pioneer in the development of a novel innate immunity stimulator, and we look forward to working with the team and supporting the advancement of KUP101 into clinical development.\u201d<\/p>\n<\/div><\/section> <\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":" Kupando, a Berlin-based biopharmaceutical company developing TLR 4\/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, has closed its Series A funding round which raised \u20ac13 million.<\/p>\n","protected":false},"author":3,"featured_media":18078,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/18077"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=18077"}],"version-history":[{"count":2,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/18077\/revisions"}],"predecessor-version":[{"id":18080,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/18077\/revisions\/18080"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/18078"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=18077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=18077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=18077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nKupando raises \u20ac13 million in Series A funding round<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nKupando, a Berlin-based biopharmaceutical company developing TLR 4\/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, has closed its Series A funding round which raised \u20ac13 million.<\/h3>\n
\n
\nShare this<\/h5>